Furthermore, our results indicate that CD271 expression and BRAFi resistance are supported by TNFα/NF-κB pathway activation, providing a pharmacologically actionable target to overcome drug resistance in melanoma therapy. The gene discussed is NFKB1; the disease is melanoma.